 Clinical and prognostic role of pro-enkephalin has tested in chronic and acute heart failure.  Pro-enkephalin was correlated with glomerular function but not with tubular dysfunction.  Pro-enkephalin did not show an additive prognostic information on top of preexisting renal markers in acute heart failure.
Introduction
Renal dysfunction is frequently observed in patients with heart failure 1 , and both baseline renal function and worsening of renal function accompanying inadequate decongestion during hospitalization is associated with prolonged hospitalization, rehospitalization, and death 2, 3 .
Enkephalins including pro-enkephalin (pro-ENK) are small endogenous opioid peptides encoded by the proenkephalin gene, and have been shown to be implicated in neurotransmission, autocrine and paracrine function, and cardiac function. Most of the early studies have focused on its role in neuronal tissues, but it is also suggested to be produced and act in non-neural tissues including heart and kidney 4 . Due to the instability of enkephalins, a stable fragment of their precursor, termed pro-ENK, has been devised as stable and reliable Page 3 of 27 surrogate plasma marker 5 . In patients with acute kidney injury after cardiac surgery, pro-ENK was shown to rapidly increase 6 . In acute myocardial infarction, increased pro-ENK was associated with renal dysfunction and predicted major cardiac events 7 . These results suggest a potential of pro-ENK as a novel cardiorenal biomarker, although its role in chronic and acute heart failure has not been established. Here, we evaluate the association between pro-ENK and indices of glomerular and tubular function and clinical outcome in patients with acute and chronic heart failure.
Methods
This study was performed in two populations. First, a cardiorenal mechanistic cohort was used to investigate the association between pro-ENK and renal function including hemodynamic parameters which were measured by radioactive tracers in patients with stable chronic heart failure 8, 9 . Second, the PROTECT (Placebo-controlled Randomized study of the selective A1 adenosine receptor antagonist rolofylline for the patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal functTion) study cohort (acute heart failure cohort) was used to study the association between pro-ENK and prognosis in patients with acute heart failure 10 . Measurement of pro-ENK was performed using a sandwich immunoassay with antibodies against the proenkephalin A 119-159 peptide by Sphingotec inc. 5, 7 . The lower detection limit was 5.5 pmol/L. Intra-and inter-assay coefficients of variation were 6.4 and 9.5% at 50 pmol/L, and 4.0 and 6.5% at 150 pmol/L, respectively. The normal value of pro-ENK was measured in a general population, and determined as 46. Renal mechanistic cohort (chronic heart failure)
Patient selection and measurement procedure of renal hemodynamic parameters have been described elsewhere 8, 9 . In brief, 120 ambulatory patients with heart failure with left ventricular ejection fraction (LVEF) <45% on stable doses of ACE inhibitor or ARB for at least one month were included at University Medical Centre Groningen. All patients who consented to participate underwent GFR and effective renal plasma flow measurement using were also determined by ELISA as previously described 9 .
Acute heart failure cohort
We also measured pro-ENK in the PROTECT study cohort. The details of the design, results, and conclusions of this study have already been published 10, 12, 13 . In brief, 2,033 patients with acute heart failure with renal function impairment (estimated creatinine clearance between 20 to 80 mL/min with Cockcroft-Gault formula) were included and randomized to rolofylline or placebo. The protocol of the PROTECT study was approved by the ethics committee at each participating center, and written informed consent was obtained from all participants. We measured pro-ENK in 1,589 patients at baseline (day 1) 1,465 patients at day 2, and 1,200
patients at day 7 as samples were available. The following biomarkers were also evaluated at We also evaluated the association between worsening renal function (WRF), pre-defined in PROTECT as a creatinine increase of ≥0.3 mg/dL from baseline (day 1) value or initiation of hemofiltration or dialysis at any time between day 1 to day 4.
The prognostic value of pro-ENK was evaluated with 1,589 AHF patients with available Pro-ENK value at baseline using three endpoints: all-cause mortality within 180 days, heart failure rehospitalization through 60 days, and death or cardiovascular or renal rehospitalization through day 60 days 14 .
Statistical analysis
In both cohorts, data are expressed as mean and standard deviation for normally distributed transformed for further analyzes. Stepwise multiple linear regression analysis was performed using backward elimination with a P value <0.10 as the criterion for retention after including all variables with P value <0.10 in univariate analysis to identify factors independently associate to pro-ENK levels.
In the acute heart failure cohort, univariate logistic regression was performed to evaluate predictability of pro-ENK for WRF. If pro-ENK was significant in univariate logistic regression, multivariable logistic regression was performed to adjust for baseline creatinine levels to evaluate additive predictability for WRF. The longitudinal trajectory of pro-ENK over time (day 1, day 2 and day 7) was assessed by using linear mixed effect models to account for withinindividual correlation of repeatedly measured values of pro-ENK. For this analysis, we excluded patients who died within 7 days. Identification of subjects was included as random effects, and time was modeled linearly. We used age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, serum sodium, log blood urea nitrogen, log creatinine, and albumin as fixed effects as these were suggested as factors of prognostic predictive value in this cohort 15 . For prognostic analysis, we adjusted log pro-ENK by a model that was previously defined for this cohort, including age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, sodium, log blood urea nitrogen, log creatinine and albumin. 15 . In this cohort, predictability of this model was confirmed to be similar to more complex models for outcome of all-cause mortality within 180 days, death or rehospitalization for any reason within 30 days, and cardiovascular or renal rehospitalization within 30 days. We evaluated prognostic predict ability of pro-ENKN in three multivariable Cox models: adjusted for age and gender 
Results

Renal mechanistic cohort
Patient characteristics
Baseline characteristics are shown in Table 1 . The mean age was 60±12 years, 75 patients (79%) were male, and mean LVEF was 29±10%. The median value of pro-ENK was 62.2 (IQR:
, and 28 (29.5%) patients had pro-ENK levels above 99 th percentile upper reference limit of pro-ENK in healthy subjects. Higher pro-ENK tertiles were associated with higher age, females, lower blood pressure, higher NYHA class, greater diuretics use and higher plasma NT-proBNP levels (all P<0.05).
Correlation between renal markers and pro-ENK
Supplemental Table 1 shows the result of univariate linear regression analysis between log pro-ENK, renal markers and renal hemodynamic parameters. pro-ENK values were strongly and significantly associated with creatinine, BUN, Urinary Albumin Excretion, Cystatin C, GFR, and RBF but not with urinary tubular markers (NAG, NGAL, and KIM-1). Table 2 shows the result of multivariable linear regression analysis for pro-ENK. In the final model (R 2 =0.616), higher log pro-ENK levels were associated with lower GFR (standardized beta = -0.377) higher BUN, higher NT-proBNP, lower NYHA class, and lower systolic blood pressure.
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Acute heart failure cohort
Patient characteristics
Baseline characteristics of the PROTECT AHF cohort according to pro-ENK tertiles are shown in Table 3 . The mean age was 71±11 years, 1049 (66%) were male, and mean LVEF was 33±
13%. The median value of pro-ENK was 104.9 (IQR: 73.7 -146.6) pmol/L (Figure 1 ), and 1092 (68.7%) patients had pro-ENK levels above 99 th percentile upper reference limit of pro-ENK in healthy subjects. At baseline, higher pro-ENK levels were associated with higher age, females, lower diastolic blood pressure, preserved LVEF (≥45%), history of diabetes, higher creatinine, higher BUN, and higher brain natriuretic peptide (BNP).
Correlation between covariates and pro-ENK
The result of univariate and multivariable linear regression analysis of pro-ENK is shown in Supplemental Table 2 and Table 2 , respectively. Serum creatinine was the primary determinant of log pro-ENK among baseline variables (standardized beta = 0.422, P<0.001), and followed by females, higher age, higher BNP, and higher BUN in PROTECT acute heart failure cohort.
Association between pro-ENK and WRF
High pro-ENK values at baseline were associated with a higher incidence of worsening renal function (Table 4 ). In univariate logistic regression, log pro-ENK was significantly associated with worsening renal function (Odds ratio: 1.47, 95% CI: 1.18-1.84, P<0.001). However, the significance was attenuated after adjustment for log creatinine (Odds ratio: 1.24, 95% CI: 0.95-1.61, P=0.119). In a sensitivity analysis, log pro-ENK was not a significant predictor of WRF with other definitions (≥25% increase or ≥25% and ≥0.3 mg/dL increase in creatinine from baseline levels) even in a univariate logistic regression analysis (data not shown).
Association of pro-ENK with prognosis
Kaplan-Meier curves of each tertile for mortality through day 180 are shown in Figure 2 . Higher tertiles of pro-ENK were associated with 180 days mortality (P<0.001). In Cox regression models, high log pro-ENK levels were significantly associated with all of the three outcomes;
death through 180 days, heart failure rehospitalization through day 60, and death or cardiovascular or renal rehospitalization through day 60 in univariable Cox regression analysis, and even after adjustment for age and gender (Model 1). Log pro-ENK was a significant predictor only for endpoint of death through day 180 even after being adjusted by age, gender, creatinine, and BUN (Model 2). However, log pro-ENK lost its significance for all of outcomes after adjustment for the PROTECT prognostic model; including age, history of heart failure hospitalization, severity of peripheral edema, systolic blood pressure, serum sodium, BUN, creatinine, and Albumin (Model 3) (Table 4 ). There was no significant interaction between rolofylline treatment and prognostic predictive ability of pro-ENK for any of outcomes (all P for interaction >0.3).
Serial changes in pro-ENK over time and prognosis
We compared the trajectory of pro-ENK values at day 1, day 2, and day 7 and percent change from baseline to day 2 and day 7 between patients with and without death through 180 days
Page 10 of 27 after excluding 29 patients who died within 7 days of admission ( Figure 3 ). Baseline pro-ENK value was higher in patients who died compared with those who were alive. In the mixed effect model, there was no significant difference between patients who died or survived with regard to absolute or relative changes over time (P=0.760 and P=0.258, respectively). Similar results were obtained for the endpoints of heart failure rehospitalization through 60 days and death or cardiovascular or renal rehospitalization through day 60 (P>0.05 for all) (Supplemental Figure 1) .
We also evaluated the prognostic importance of percent change in pro-ENK from baseline (day 1) to day 2 and from baseline to day 7 as a numeric variable, and neither showed independent prognostic information in multivariate Cox regression analysis (Supplemental Table 3 ).
Discussion
In acute and chronic heart failure, pro-ENK levels were higher in acute HF compared with chronic HF. Pro-ENK was clearly associated with renal blood flow and glomerular filtration rate but not with tubular function. In patients with heart failure, pro-ENK was associated with clinical outcome, but after adjustments for established prognostic predictors including preexisting renal markers, this association was lost. Therefore, pro-ENK seems to be a renal marker, but does not seem to have additive value on top of the established prognostic markers.
Pro-ENK as a renal biomarker in patients with heart failure
The endogenous opioid system is one of the most studied innate pain-relieving systems. In addition, the endogenous opioid system has also been suggested to have a negative effect on the cardiovascular system. Two observational studies suggested that activity of the endogenous opioid system was activated in patients with heart failure compared with healthy subjects 16, 17 .
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Additionally, in an experimental dog model of congestive heart failure, delta-opioid receptor (OPR) was specified as a more relevant receptor subtype among several OPRs in terms of hemodynamic regulation 18 . In this study, a selective antagonist for delta-OPR increased aortic pressure, cardiac output, and blood flow to the myocardium and kidney. These results suggested that delta-OPR plays a main role in the opioid system as a cardiovascular modulator, and measuring activity of enkephalin -a specific peptide to delta-OPR -might be useful to evaluate the effect of the opioid system in patients with heart failure. Recently, pro-ENK was suggested as a stable and reliable surrogate marker of enkephalin and it became possible to evaluate enkephalin activity in vivo 5 .
In the present study, we showed that levels of pro-ENK were relatively high in patients with both acute and chronic heart failure when pro-ENK value derived from normal subject was used as reference. Furthermore, both in the chronic and acute heart failure cohorts we found a consistent association between pro-ENK and several renal markers. Moreover, precise evaluation of renal function in the chronic heart failure cohort showed that pro-ENK levels were strongly associated with renal blood flow and glomerular filtration rate. These results are in agreement with the finding that delta-OPR was highly expressed in the kidney and inhibition of delta-OPR increased kidney blood flow in an experimental heart failure model 4, 18 . Moreover, pro-ENK was positively correlated with albuminuria in the chronic heart failure cohort. These findings show that pro-ENK is a novel renal marker. The pathophysiologic mechanism or rather determinants of pro-ENK including renal clearance has to be evaluated in future studies.
We evaluated the association between pro-ENK and worsening renal function in acute heart failure, and found that pro-ENK was not a predictor of worsening renal function in patients with heart failure independent from serum creatinine. This is in line with a previous study that evaluated the association between pro-ENK values before surgery and acute kidney injury in patients undergoing cardiac surgery. In this study, baseline pro-ENK values were strongly associated with baseline creatinine. Pro-ENK levels were also associated with acute kidney injury after surgery, but did not outweigh creatinine 6 . These and our results showed that the association between pro-ENK and worsening renal function can be attributed to the significant association with creatinine, and pro-ENK by itself provides limited additive information to creatinine in terms of changes in renal function.
Prognostic information of pro-ENK in heart failure
In our present analysis, pro-ENK was not an independent predictor of prognosis in acute heart failure cohort in spite of its association with renal function and severity of heart failure. This result suggests that pro-ENK provides limited additional prognostic information to preexisting prognostic markers of patients with heart failure including renal biomarkers.
Our findings are inconsistent with previous two studies which investigated prognostic role of pro-ENK in patients with myocardial infarction and non-symptomatic patients with heart failure, where higher pro-ENK levels were an independent predictor of a combined endpoint of death and adverse events even after adjustment for other prognostic factors 7, 19 . This discordance might be due to a difference in study population. Another possible explanation is an association between pro-ENK and BUN. In the aforementioned study of myocardial infarction patients, pro-ENK was an independent predictor of mortality after being adjustment for the Global Registry of Acute Coronary Events (GRACE) model 20 , and pro-ENK showed incremental prognostic information. However, the GRACE model does not include information about BUN, and as a consequence, it is unclear whether pro-ENK would have been a significant predictor of events if the model would have been adjusted for BUN. Recent studies showed that BUN was an Page 13 of 27 independent predictor of mortality also in acute myocardial infarction patients even after being adjusted by eGFR 21, 22 and indeed pro-ENK was significantly and strongly correlated with BUN in our cohort. Recently, Arbit et al. investigated the role of pro-ENK in patients referred to echocardiography and categorized into stage A or B HF (symptomatic HF patients were excluded). Pro-ENK correlated with serum creatinine and eGFR, and was an independent predictor of worse prognosis after adjustment for some prognostic factors. However, in contrast to the present study, these patients were asymptomatic and were not adjusted for BUN, which was a strong confounder in our study 19 . The relationship between pro-ENK and BUN might be an explanation why pro-ENK was an independent prognostic predictor in these previous studies but not in our cohort.
Limitations
This study has important limitations due to its retrospective character. In the chronic HF cohort, number of patients were limited so that prognostic predictability of pro-ENK in a chronic heart failure population remains to be elucidated. In the acute heart failure cohort, only patients with heart failure with mild renal impairment were included by study design. Echocardiographic measurements were obtained in only less than half of all patients. Moreover, pro-ENK levels
were not available in some patient of both cohorts due to availability of plasma, which could have influenced the results despite the fact that there was no significant difference in event rate
for any endpoints between patients with available samples and those without (all P value >0.5).
Conclusion
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Pro-ENK levels were higher in acute heart failure when it compared with chronic heart failure.
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